Total Funding
54
45
Total FundingPost-IPO Equity raised
Growth Score
-2 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
145513
ContraFect is a biotechnology company researching the use of monoclonal antibodies to treat life-threatening infectious diseases.
- Cara Cassino: Chief Medical Officer and Executive Vice President of Research and Development
Michael Wittekind: Chief Scientific Officer
About the Company
ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are
produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria.
The company was founded in 2008 and is headquartered in Yonkers, New York.
